テノホビルジソプロキシルの世界市場レポート 2025年

テノホビルジソプロキシル市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.6％で47億2,000万米ドルに成長します。予測期間中の成長は、長時間作用型テノホビル製剤に対する需要の高まり、新規抗ウイルス剤との併用療法への注目の高まり、新規テノホビル併用療法に対する規制当局の承認の高まり、小児用製剤への重点化、曝露後予防におけるテノホビルの使用の増加などによると考えられます。主な動向としては、新規ドラッグデリバリーシステムの開発、医薬品開発における人工知能の統合、併用療法の進展、ナノテクノロジーを利用したデリバリーの革新、合剤療法の進展などが挙げられます。

HIVとAIDSの有病率の増加がテノホビルジソプロキシル市場の成長を牽引すると予想されます。HIVおよびAIDSは、CD4細胞を攻撃することで免疫系を弱め、体を感染症や病気にかかりやすくする慢性ウイルス感染症です。これらの疾患の有病率の上昇は、無防備な性的接触、認識不足、ヘルスケアへのアクセス制限、薬剤耐性ウイルス株の出現などの要因によるものです。HIV/AIDS患者の増加により、治療と予防に使用される主要な抗レトロウイルス薬であるテノホビルジソプロキシルの需要が増加しています。例えば、2024年7月、スイスに本部を置く政府機関である国連合同エイズ計画（UNAIDS）は、2022年末までに世界で約3,950万人がHIVに感染し、同年に約130万人の新規感染が記録されたと報告しました。さらに、2022年にはエイズ関連疾患による死亡者が世界で約63万人発生し、2023年にはHIVとともに生きる人の数は3,990万人（3,610万人～4,460万人）に増加します。その結果、HIVとAIDSの有病率の増加がテノホビルジソプロキシル市場の成長を促進しています。

また、B型肝炎の有病率の増加もテノホビルジソプロキシル市場の拡大に寄与すると予想されます。B型肝炎は肝臓を標的とするウイルス感染症で、感染した血液や体液との接触によって感染し、急性および慢性の疾患を引き起こす可能性があります。周産期感染、安全でない医療行為、ワクチン接種率の不足、感染集団における慢性感染の持続といった要因が、B型肝炎患者の増加を促進しています。テノホビルジソプロキシルはB型慢性肝炎の治療薬として広く使用されており、ウイルスの複製を抑え、肝障害を最小限に抑えるのに役立っています。例えば、2023年3月、米国の公衆衛生機関である疾病対策予防センター（CDC）は、米国では58万人から240万人がB型肝炎に感染していると推定しており、その約3分の2は自分の症状に気づいていない可能性があるとしています。その結果、B型肝炎の有病率の増加が、テノホビルジソプロキシルの需要に寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界テノホビルジソプロキシルPESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のテノホビルジソプロキシル市場：成長率分析
• 世界のテノホビルジソプロキシル市場の実績：規模と成長, 2019-2024
• 世界のテノホビルジソプロキシル市場の予測：規模と成長, 2024-2029, 2034F
• 世界テノホビルジソプロキシル総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のテノホビルジソプロキシル市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 錠剤
• 粉
• 世界のテノホビルジソプロキシル市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オンライン薬局
• 小売薬局
• 卸売業者または販売業者
• 世界のテノホビルジソプロキシル市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• クリニック
• 世界のテノホビルジソプロキシル市場タブレットの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 単剤錠
• 固定用量配合錠
• 世界のテノホビルジソプロキシル市場、粉末の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 経口粉末
• 再構成可能な粉末

第7章 地域別・国別分析

• 世界のテノホビルジソプロキシル市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のテノホビルジソプロキシル市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• テノホビルジソプロキシル市場：競合情勢
• テノホビルジソプロキシル市場：企業プロファイル
  • Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceuticals Limited Overview, Products and Services, Strategy and Financial Analysis
  • Cipla Ltd Overview, Products and Services, Strategy and Financial Analysis
  • Lupin Limited Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Mylan NV
• Blanver
• SMS Pharmaceuticals
• Bajaj Healthcare
• Mangalam Drugs & Organics Ltd
• Nortec Quimica
• Arene Lifesciences
• Cdymax
• HRV Global Life Sciences
• Pipelinepharma
• Qilu Pharmaceutical
• Jai Radhe Sales
• Sinoway Industrial Co. Ltd
• Aurisco Pharmaceutical
• Huangshi Fuertai Pharmaceutical Tech Co. Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• テノホビルジソプロキシル市場2029：新たな機会を提供する国
• テノホビルジソプロキシル市場2029：新たな機会を提供するセグメント
• テノホビルジソプロキシル市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Tenofovir disoproxil is a medication used for treating HIV-1 infection and chronic hepatitis B. As a prodrug of tenofovir, it converts into its active form in the body, inhibiting viral replication. It belongs to the nucleotide reverse transcriptase inhibitors (NRTIs) class, which blocks a crucial enzyme required for viral multiplication.

The primary forms of tenofovir disoproxil are tablets and powder. Tablets are solid medicinal forms designed for easy swallowing, dissolving in the digestive system to release the active ingredient either gradually or immediately. The medication is distributed through online pharmacies, retail pharmacies, and wholesalers or distributors, with applications primarily in hospitals and clinics.

The tenofovir disoproxil market research report is one of a series of new reports from The Business Research Company that provides tenofovir disoproxil market statistics, including the tenofovir disoproxil industry's global market size, regional shares, competitors with a tenofovir disoproxil market share, detailed tenofovir disoproxil market segments, market trends and opportunities, and any further data you may need to thrive in the tenofovir disoproxil industry. This tenofovir disoproxil market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The tenofovir disoproxil market size has grown strongly in recent years. It will grow from $3.58 billion in 2024 to $3.79 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period can be credited to increased awareness and early detection of viral infections, the rising prevalence of hepatitis B infections, the expansion of generic drug manufacturing for tenofovir disoproxil, a growing number of clinical trials supporting its efficacy, and increased healthcare funding for infectious disease treatment.

The tenofovir disoproxil market size is expected to see strong growth in the next few years. It will grow to $4.72 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth during the forecast period can be credited to the rising demand for long-acting tenofovir formulations, an increasing focus on combination therapies with newer antivirals, growing regulatory approvals for novel tenofovir combinations, a heightened emphasis on pediatric formulations, and the increasing use of tenofovir in post-exposure prophylaxis. Key trends include the development of novel drug delivery systems, the integration of artificial intelligence in drug development, advancements in combination therapies, innovations in nanotechnology-based delivery, and progress in fixed-dose combination therapies.

The increasing prevalence of HIV and AIDS is expected to drive the growth of the tenofovir disoproxil market. HIV and AIDS are chronic viral infections that weaken the immune system by attacking CD4 cells, making the body more susceptible to infections and diseases. The rising prevalence of these conditions is attributed to factors such as unprotected sexual contact, lack of awareness, limited access to healthcare, and the emergence of drug-resistant virus strains. The growing number of HIV and AIDS cases is increasing the demand for tenofovir disoproxil, a key antiretroviral drug used for treatment and prevention. For example, in July 2024, the Joint United Nations Programme on HIV/AIDS (UNAIDS), a Switzerland-based government organization, reported that by the end of 2022, approximately 39.5 million people were living with HIV worldwide, with about 1.3 million new infections recorded that year. Additionally, in 2022, around 630,000 deaths from AIDS-related illnesses occurred globally, with the number of people living with HIV rising to 39.9 million (36.1 million-44.6 million) in 2023. As a result, the increasing prevalence of HIV and AIDS is fueling the growth of the tenofovir disoproxil market.

The growing prevalence of hepatitis B is also expected to contribute to the expansion of the tenofovir disoproxil market. Hepatitis B is a viral infection that targets the liver and can lead to both acute and chronic disease, transmitted through contact with infected blood or bodily fluids. Factors such as perinatal transmission, unsafe medical practices, lack of vaccination coverage, and the persistence of chronic infections in affected populations are driving the rise in hepatitis B cases. Tenofovir disoproxil is a widely used treatment for chronic hepatitis B, helping to suppress viral replication and minimize liver damage. For instance, in March 2023, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, estimated that between 580,000 and 2.4 million people in the United States are living with hepatitis B infection, with about two-thirds potentially unaware of their condition. Consequently, the increasing prevalence of hepatitis B is contributing to the demand for tenofovir disoproxil.

Leading companies in the tenofovir disoproxil market are focusing on innovative formulations, such as combination therapies, to enhance HIV/AIDS treatment and maintain a competitive edge. Combination therapy involves the simultaneous use of two or more treatments to improve therapeutic outcomes and patient well-being. For instance, in July 2022, Gilead Sciences Inc., a US-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Vemlidy (tenofovir alafenamide) for the treatment of chronic hepatitis B virus (HBV) infection in pediatric patients aged six years and older, weighing at least 25 kg, with compensated liver disease. The FDA's approval was based on data from a Phase II clinical trial demonstrating the drug's safety and efficacy in children as young as six years old.

Major players in the tenofovir disoproxil market are Gilead Sciences Inc., Viatris Inc., Teva Pharmaceuticals Limited, Cipla Ltd, Lupin Limited, Mylan NV, Blanver, SMS Pharmaceuticals, Bajaj Healthcare, Mangalam Drugs & Organics Ltd, Nortec Quimica, Arene Lifesciences, Cdymax, HRV Global Life Sciences, Pipelinepharma, Qilu Pharmaceutical, Jai Radhe Sales, Sinoway Industrial Co. Ltd, Aurisco Pharmaceutical, Huangshi Fuertai Pharmaceutical Tech Co. Ltd.

North America was the largest region in the tenofovir disoproxil market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tenofovir disoproxil report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tenofovir disoproxil market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tenofovir disoproxil market consists of sales of active pharmaceutical ingredients (APIs), branded formulations, generic formulations, and combination therapies. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tenofovir Disoproxil Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tenofovir disoproxil market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tenofovir disoproxil ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tenofovir disoproxil market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Tablet; Powder
• 2) By Distribution Channel: Online Pharmacies; Retail Pharmacies; Wholesalers Or Distributors
• 3) By Application: Hospital; Clinic
• Subsegments:
• 1) By Tablet: Single-Drug Tablets; Fixed-Dose Combination Tablets
• 2) By Powder: Oral Powder; Reconstitutable Powder
• Companies Mentioned: Gilead Sciences Inc.; Viatris Inc.; Teva Pharmaceuticals Limited; Cipla Ltd; Lupin Limited
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Tenofovir Disoproxil Market Characteristics

3. Tenofovir Disoproxil Market Trends And Strategies

4. Tenofovir Disoproxil Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Tenofovir Disoproxil Growth Analysis And Strategic Analysis Framework

• 5.1. Global Tenofovir Disoproxil PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Tenofovir Disoproxil Market Growth Rate Analysis
• 5.4. Global Tenofovir Disoproxil Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Tenofovir Disoproxil Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Tenofovir Disoproxil Total Addressable Market (TAM)

6. Tenofovir Disoproxil Market Segmentation

• 6.1. Global Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tablet
• Powder
• 6.2. Global Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Online Pharmacies
• Retail Pharmacies
• Wholesalers Or Distributors
• 6.3. Global Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital
• Clinic
• 6.4. Global Tenofovir Disoproxil Market, Sub-Segmentation Of Tablet, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Single-Drug Tablets
• Fixed-Dose Combination Tablets
• 6.5. Global Tenofovir Disoproxil Market, Sub-Segmentation Of Powder, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral Powder
• Reconstitutable Powder

7. Tenofovir Disoproxil Market Regional And Country Analysis

• 7.1. Global Tenofovir Disoproxil Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Tenofovir Disoproxil Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Tenofovir Disoproxil Market

• 8.1. Asia-Pacific Tenofovir Disoproxil Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Tenofovir Disoproxil Market

• 9.1. China Tenofovir Disoproxil Market Overview
• 9.2. China Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Tenofovir Disoproxil Market

• 10.1. India Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Tenofovir Disoproxil Market

• 11.1. Japan Tenofovir Disoproxil Market Overview
• 11.2. Japan Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Tenofovir Disoproxil Market

• 12.1. Australia Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Tenofovir Disoproxil Market

• 13.1. Indonesia Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Tenofovir Disoproxil Market

• 14.1. South Korea Tenofovir Disoproxil Market Overview
• 14.2. South Korea Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Tenofovir Disoproxil Market

• 15.1. Western Europe Tenofovir Disoproxil Market Overview
• 15.2. Western Europe Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Tenofovir Disoproxil Market

• 16.1. UK Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Tenofovir Disoproxil Market

• 17.1. Germany Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Tenofovir Disoproxil Market

• 18.1. France Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Tenofovir Disoproxil Market

• 19.1. Italy Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Tenofovir Disoproxil Market

• 20.1. Spain Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Tenofovir Disoproxil Market

• 21.1. Eastern Europe Tenofovir Disoproxil Market Overview
• 21.2. Eastern Europe Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Tenofovir Disoproxil Market

• 22.1. Russia Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Tenofovir Disoproxil Market

• 23.1. North America Tenofovir Disoproxil Market Overview
• 23.2. North America Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Tenofovir Disoproxil Market

• 24.1. USA Tenofovir Disoproxil Market Overview
• 24.2. USA Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Tenofovir Disoproxil Market

• 25.1. Canada Tenofovir Disoproxil Market Overview
• 25.2. Canada Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Tenofovir Disoproxil Market

• 26.1. South America Tenofovir Disoproxil Market Overview
• 26.2. South America Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Tenofovir Disoproxil Market

• 27.1. Brazil Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Tenofovir Disoproxil Market

• 28.1. Middle East Tenofovir Disoproxil Market Overview
• 28.2. Middle East Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Tenofovir Disoproxil Market

• 29.1. Africa Tenofovir Disoproxil Market Overview
• 29.2. Africa Tenofovir Disoproxil Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Tenofovir Disoproxil Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Tenofovir Disoproxil Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Tenofovir Disoproxil Market Competitive Landscape And Company Profiles

• 30.1. Tenofovir Disoproxil Market Competitive Landscape
• 30.2. Tenofovir Disoproxil Market Company Profiles
  • 30.2.1. Gilead Sciences Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Viatris Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Teva Pharmaceuticals Limited Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Cipla Ltd Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Lupin Limited Overview, Products and Services, Strategy and Financial Analysis

31. Tenofovir Disoproxil Market Other Major And Innovative Companies

• 31.1. Mylan NV
• 31.2. Blanver
• 31.3. SMS Pharmaceuticals
• 31.4. Bajaj Healthcare
• 31.5. Mangalam Drugs & Organics Ltd
• 31.6. Nortec Quimica
• 31.7. Arene Lifesciences
• 31.8. Cdymax
• 31.9. HRV Global Life Sciences
• 31.10. Pipelinepharma
• 31.11. Qilu Pharmaceutical
• 31.12. Jai Radhe Sales
• 31.13. Sinoway Industrial Co. Ltd
• 31.14. Aurisco Pharmaceutical
• 31.15. Huangshi Fuertai Pharmaceutical Tech Co. Ltd

32. Global Tenofovir Disoproxil Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Tenofovir Disoproxil Market

34. Recent Developments In The Tenofovir Disoproxil Market

35. Tenofovir Disoproxil Market High Potential Countries, Segments and Strategies

• 35.1 Tenofovir Disoproxil Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Tenofovir Disoproxil Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Tenofovir Disoproxil Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer